Paid Clinical Trials Tacoma
Discover 1,374 paid clinical trials in Tacoma, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
OfatumumabPharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT06869785
Conditions
Relapsing Multiple Sclerosis (RMS)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Ofatumumab approved dose
Ofatumumab new dose
XYOSTED®52 Week Study of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Sponsor:
Halozyme Therapeutics
Location:
Code:
NCT06689085
Conditions
Hypogonadism, Male
Eligibility Criteria
Sex: Male
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Testosterone enanthate
ABBV-383A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
Sponsor:
TeneoOne Inc.
Location:
Code:
NCT05650632
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ABBV-383
STK-012STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
Sponsor:
Synthekine
Location:
Code:
NCT05098132
Conditions
Advanced Solid Tumor
Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Malignant Melanoma
Renal Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
STK-012
pembrolizumab
pemetrexed
carboplatin
Rilvegostomig & PembrolizumabA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Sponsor:
AstraZeneca
Location:
Code:
NCT06692738
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Rilvegostomig
Pembrolizumab
Carboplatin
Paclitaxel
Nab-paclitaxel
Interested in new trials?
Get alerts for new trials in your area by subscribing now
NEO212Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Sponsor:
Neonc Technologies, Inc.
Location:
Code:
NCT06047379
Conditions
Diffuse Astrocytoma, IDH-Mutant
Glioblastoma, IDH-wildtype
Brain Metastases, Adult
Cervical Cancer
Colorectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NEO212 Oral Capsule
Ipilimumab
Pembrolizumab
Nivolumab
Regorafenib
VolrustomigA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Sponsor:
AstraZeneca
Location:
Code:
NCT06129864
Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
volrustomig
ABBV-706, Budigalimab, Cisplatin, CarboplatinStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Sponsor:
AbbVie
Location:
Code:
NCT05599984
Conditions
Advanced Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ABBV-706
Cisplatin
Budigalimab
Carboplatin
LUT014LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Sponsor:
Lutris Pharma Ltd.
Location:
Code:
NCT04759664
Conditions
EGFRI Induced Acneiform Lesions
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LUT014 Gel (Dose 1)
LUT014 Gel (Dose 2)
Placebo
Targeted TherapiesStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Sponsor:
AbbVie
Location:
Code:
NCT06548542
Conditions
Crohn's Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Risankizumab
Lutikizumab
ABBV-382